Tirzepatide vs Zepbound 2026

Yes. Tirzepatide is the International Nonproprietary Name (INN) — the generic name of the active drug molecule. Zepbound is Eli Lilly's brand name for tirzepatide when prescribed for chronic weight management. Mounjaro is Eli Lilly's brand name for the same molecule when prescribed for Type 2 diabetes. The chemistry is identical: all are once-weekly subcutaneous injections of the same dual GLP-1/GIP receptor agonist. The difference is the indication (weight vs. diabetes), dosing/titration schedule on the packaging, and regulatory label — not the drug itself.

Branded Zepbound costs approximately $1,086/month at full retail cash price as of May 2026. Eli Lilly's Zepbound savings card can reduce that to roughly $399/month for commercially-insured patients who qualify. Compounded tirzepatide from verified telehealth providers ranges from $167–$299/month depending on plan length and provider. The gap between compounded and branded is $700–$900/month for most cash-paying patients — approximately $8,400–$10,800 per year.

The legal status has changed significantly in 2025–2026. The FDA declared the tirzepatide shortage resolved on March 5, 2025. For 503A pharmacies (patient-specific compounders), enforcement of the shortage-based compounding allowance ramped up starting April 1, 2025. For 503B outsourcing facilities, FDA published a proposal on April 30, 2026 to remove tirzepatide from the "bulks list" — meaning 503B compounders would no longer be able to produce it after the comment period closes (June 29, 2026). As of May 2026, 503A compounding remains legal under clinical necessity carve-outs; the regulatory landscape continues to evolve.

The active molecule is the same — tirzepatide in both cases. Branded Zepbound is produced under FDA-regulated GMP manufacturing with rigorous quality controls. Compounded tirzepatide is produced by pharmacy compounders under different oversight frameworks (503A or 503B). There are no head-to-head clinical trials comparing compounded vs. branded tirzepatide efficacy, because they are legally different products (compounded drugs are not FDA-approved as such). If manufacturing quality and regulatory certainty are your primary concerns, branded Zepbound is the safer choice. If cost is the primary concern and you are working with a licensed prescriber, compounded is significantly less expensive.

Zepbound and Mounjaro are both brand names for tirzepatide manufactured by Eli Lilly — the same molecule. The difference is the FDA approval indication: Mounjaro is FDA-approved for Type 2 diabetes management; Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30 (or ≥27 with a weight-related condition). Dosing auto-injector pens are physically identical. Some patients who have Mounjaro covered for T2D may also receive weight-loss benefit, but prescribing off-label for weight loss (Mounjaro for non-diabetics) depends on prescriber judgment and insurer policy.

Yes — as of May 2026, several telehealth providers offer compounded tirzepatide with a valid prescription from a licensed prescriber. Verified options in our stack include TMates ($167–$297/mo depending on plan), MEDVi ($229–$299/mo, Gronk-verified), Eden Health ($229–$249/mo), and Embody ($299/mo flat). All require a brief medical intake and prescriber review. See our Best Compounded Tirzepatide page for a full ranked comparison.